Yesterday, mid cap biotech stock United Therapeutics Corporation (NASDAQ: UTHR) soared 30.36% after announced FDA approval of Orenitram as an oral treatment for pulmonary arterial hypertension (PAH), meaning investors should take a closer look at the stock along with the performance of peers like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and the SPDR S&P Biotech ETF (NYSEARCA: XBI).
What is United Therapeutics Corporation?
Small cap United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. While focused on the cardiovascular field, United Therapeutics Corporation is also laying important foundations for future franchises in the treatment of cancer and infectious diseases.
Best Mid Cap Stocks To Invest In 2015: Hawkins Inc. (HWKN)
Hawkins, Inc. distributes bulk chemicals, as well as blends, manufactures, and distributes specialty chemicals. The company operates through two segments, Industrial and Water Treatment. The Industrial segment provides industrial chemicals, products, and services primarily to the agriculture, energy, electronics, food, chemical processing, pulp and paper, pharmaceutical, medical device, and plating industries. This segment primarily offers acids, alkalis, and industrial and food-grade salts; and receives, stores, and distributes various chemicals, including liquid caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. In addition, it manufactures sodium hypochlorite, agricultural products, and certain food-grade products comprising Cheese-Phos liquid phosphate, lactates, and other blended products; repackages water treatment and bulk industrial chemicals; and performs custom blending of certain chemicals, and contract and pr ivate label packaging for household chemicals. This segment primarily conducts its operations through distribution centers and terminal operations. The Water Treatment segment provides chemicals, equipment, and solutions for potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. Hawkins, Inc. was founded in 1938 and is based in Minneapolis, Minnesota.
- [By Seth Jayson]
Hawkins (Nasdaq: HWKN ) reported earnings on May 29. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q4), Hawkins met expectations on revenues and beat expectations on earnings per share.
Best Mid Cap Stocks To Invest In 2015: Standard Parking Corporation(STAN)
Standard Parking Corporation provides parking management, ground transportation, and other ancillary services to commercial, institutional, and municipal clients in the United States and Canada. Its services include collection and deposit of parking revenues; daily housekeeping; restriping of the parking stalls; maintenance of parking equipment, such as ticket dispensing machines, parking gate arms, and fee computers; painting of walkways, curbs, ceilings, walls, and other facility surfaces; and snow removal from sidewalks and driveways. The company also provides shuttle bus vehicles and drivers to operate them in support of on-airport car rental operations, as well as private off-airport parking locations; and ancillary ground transportation services at airports, such as taxi and livery dispatch, concierge-type ground transportation information, and support services for arriving passengers. In addition, it offers shuttle bus services, on-street parking meter collection, a nd other parking enforcement services for municipalities; and valet parking and shuttle bus services for the medical center and hospital markets. The company serves private and public owners, municipalities, managers and developers of office buildings, residential properties, commercial properties, shopping centers and other retail properties, sports and special event complexes, hotels, and hospitals and medical centers. As of December 31, 2011, it managed approximately 2,200 parking facility locations containing approximately 1.2 million parking spaces in approximately 345 cities; operated 147 parking-related service centers serving 61 airports; and a fleet of approximately 550 shuttle buses. The company was founded in 1929 and is headquartered in Chicago, Illinois.
- [By Namitha Jagadeesh]
Elekta AB dropped 4.3 percent after posting quarterly profit that missed forecasts. Standard Chartered (STAN) Plc slid 6.6 percent. PSA Peugeot Citroen advanced 2.4 percent as Goldman Sachs Group Inc. added the shares to its conviction-buy list.
- [By Namitha Jagadeesh]
A gauge of banking shares in the FTSE 350 Index reversed earlier gains, declining 0.5 percent. Standard Chartered Plc (STAN) fell 1.8 percent to 1,470 pence and Royal Bank of Scotland Group Plc lost 2.6 percent to 276.7 pence.
Best Mid Cap Stocks To Invest In 2015: CMS Energy Corp (CMS)
CMS Energy Corporation (CMS Energy) is an energy company operating primarily in Michigan. CMS Energy is the parent holding company of several subsidiaries, including Consumers Energy Company (Consumers) and CMS Enterprises Company (CMS Enterprises). Consumers is an electric and gas utility, and CMS Enterprises, primarily a domestic independent power producer. Consumers serves individuals and businesses operating in the alternative energy, automotive, chemical, metal, and food products industries, as well as a diversified group of other industries. CMS Enterprises, through its subsidiaries and equity investments, is engaged primarily in independent power production and owns power generation facilities fueled mostly by natural gas and biomass. CMS Energy operates in three business segments: electric utility, gas utility and enterprises, its non-utility operations and investments. EnerBank USA (EnerBank), a wholly owned subsidiary of CMS Energy, which provides unsecured consu mer installment loans for financing home improvements.
CONSUMERS ELECTRIC UTILITY
Consumers’ electric utility operations include the generation, purchase, distribution, and sale of electricity. During the year ended December 31, 2011, Consumers’ electric deliveries were 38 billion kilowatt hour, which included Retail Open Access (ROA) deliveries of four billion kilowatt hour. Consumers’ distribution system includes 413 miles of high-voltage distribution radial lines operating at 120 kilovolts or above; ,244 miles of high-voltage distribution overhead lines operating at 23 kilovolts and 46 kilovolts; 17 miles of high-voltage distribution underground lines operating at 23 kilovolts and 46 kilovolts; 55,953 miles of electric distribution overhead lines; 10,112 miles of underground distribution lines, and substations with an aggregate transformer capacity of 24 million thousand volt-amperes.
At December 31, 2011, Consumers’ electri c generating system consisted of coal generation, oil/gas/st! eam generation, hydroelectric and gas/oil combustion turbine. At December 31, 2011, Consumers had contracts to purchase coal through 2014. At December 31, 2011, Consumers had 86% of its 2012 expected coal requirements under contract, as well as a 41-day supply of coal on hand. During 2011, Consumers purchased 53% of the electricity it provided to customers through long-term power purchase agreements (PPAs), seasonal purchases, and the Midwest Energy Market. Consumers offers its generation into the Midwest Energy Market on a day-ahead and real-time basis and bids for power in the market to serve the demand of its customers. Consumers is a net purchaser of power and supplements its generation capability with purchases from the Midwest Energy Market to meet its customers’ needs during peak demand periods.
CONSUMERS GAS UTILITY
Consumers’ gas utility operations include the purchase, transmission, storage, distribution, and sale of natural gas. Con sumers’ gas utility customer base consists of a mix of residential, commercial, and diversified industrial customers in Michigan’s Lower Peninsula. In 2011, deliveries of natural gas, including off-system transportation deliveries, through Consumers’ pipeline and distribution network, totaled 337 billion cubic feet of gas, which included Gas Customer Choice (GCC) deliveries of 48 billion cubic feet of gas. Consumers’ gas utility operations are seasonal. During 2011, 46% of the natural gas supplied to all customers during the winter months was supplied from storage.
Consumers’ gas distribution and transmission system located in Michigan’s Lower Peninsula consists of 26,623 miles of distribution mains; 666 miles of transmission lines; seven compressor stations with a total of 150,635 installed and available horsepower, and 15 gas storage fields with an aggregate storage capacity of 307 billion cubic feet of gas and a working storage capacity of 142 bil lion cubic feet of gas. In 2011, Consumers purchased 70% of ! the gas i! t delivered from United States producers and 10% from Canadian producers. The remaining 20% was purchased from authorized GCC suppliers and delivered by Consumers to customers in the GCC program.
CMS Energy’s enterprises segment, through various subsidiaries and certain equity investments, is engaged primarily in domestic independent power production and the marketing of independent power production. At December 31, 2011, CMS Energy had ownership interests in independent power plants totaling 1,135 gross megawatts or 1,034 net megawatts. CMS Energy Resource Management (ERM) purchases and sells energy commodities in support of CMS Energy’s generating facilities and continues to focus on optimizing CMS Energy’s independent power production portfolio. In 2011, CMS ERM marketed 17 billion cubic feet of natural gas and 2,417 gigawatt-hour of electricity.
- [By Richard Stavros]
Michigan-based ITC Holdings Corp (NYSE: ITC) is the largest electric transmission company in the US. The company is in charge of the electric transmission system formerly owned by DTE Energy Holding Co (NYSE: DTE) and CMS Energy Corp (NYSE: CMS).
- [By Marc Bastow]
Michigan-based energy company CMS Energy (CMS) raised its quarterly dividend 6% to 27 cents per share, payable on Feb. 28 to shareholders of record as of Feb. 7.
CMS Dividend Yield: 4.02%
- [By Holly LaFon]
Most investors, analysts, media, and government officials say this should always be the goal, and they are right. However, UoP’s typical students are not the eighteen year olds grad uating from high school figuring out whether they should attend a private or public university. UoP’s typical student is single, twenty – eight years old, a minority single – mother, first in her family to attend college, and someone who is 3 Centers for Medicare & Medicaid Services (CMS) via WellCare Health Plans, Inc. 2012 Annual Report on Form 10 – K trying to improve h er career skills and compete in today’s fierce labor market. Among the biggest obstacles for this cohort is keeping their child, or children, healthy and in school so they can finish school themselves.
Best Mid Cap Stocks To Invest In 2015: BioFuel Energy Corp.(BIOF)
BioFuel Energy Corp. produces and sells ethanol and its co-products in the United States. The company offers dried and wet distillers grains with solubles, corn oil, and carbon dioxide. It operates 2 ethanol production facilities located in Wood River, Nebraska and Fairmont, Minnesota with a combined production capacity of approximately 220 million gallons per year. The company sells its products to independent third party marketers and distributors. The company was founded in 2006 and is headquartered in Denver, Colorado.
- [By Roberto Pedone]
BioFuel Energy (BIOF) is engaged in the production and sale of ethanol and its co-products through its two ethanol production facilities located in Nebraska and Minnesota. This stock closed up 9.4% to $4.04 in Tuesday’s trading session.
Tuesday’s Range: $3.69-$4.04
52-Week Range: $2.70-$10.75
Tuesday’s Volume: 152,000
Three-Month Average Volume: 57,949
From a technical perspective, BIOF soared higher here back above its 50-day moving average of $3.76 with above-average volume. This move is quickly pushing shares of BIOF within range of triggering a major breakout trade. That trade will hit if BIOF manages to take out some near-term overhead resistance levels at $3.99 to $4.12 with high volume. At last check, BIOF hit an intraday high of $4.04 and volume was well above its three-month average action of 57,949 shares.
Traders should now look for long-biased trades in BIOF as long as it’s trending above its 50-day at $3.76 or above more near-term support at $3.50 and then once it sustains a move or close above those breakout levels with volume that hits near or above 57,949 shares. If that breakout hits soon, then BIOF will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day of $4.63 to $5.19. Any high-volume move above $5.19 will then put $5.50 to $6 within range for shares of BIOF.
Best Mid Cap Stocks To Invest In 2015: TIBCO Software Inc.(TIBX)
TIBCO Software Inc. provides middleware and infrastructure software worldwide. It offers products in the areas of service-oriented architecture (SOA) and core infrastructure; business optimization; and process automation and collaboration. Its SOA and core infrastructure product line helps organizations integrate their disparate systems and move towards flexible infrastructure comprised of services or discrete data components that can be assembled, orchestrated, and reused; and enables the creation, management, and virtualization of heterogeneous services. The company?s business optimization product portfolio assists organizations analyze data to create information and deliver it to employees, customers, and partners; and employees perform their jobs, and customers get information, as well as helps managers identify and analyze problems and opportunities. Its process automation and collaboration software helps organizations coordinate manual and automated process flows th at span their business and enables employees to collaborate in real-time using social media; and coordinate the human and electronic resources inside a business and its network of customers and partners. The company also provides professional services, which include consulting services that comprise systems planning and design, installation, and systems integration; maintenance and support; training; and hosted services. It serves various industries, such as financial services, telecommunications, government, energy, life sciences, insurance, logistics, manufacturing, retail, and transportation. The company sells its products through direct sales force, as well as through software vendors, resellers, and systems integrators. TIBCO Software Inc. was founded in 1985 and is headquartered in Palo Alto, California.
- [By Lauren Pollock]
Tibco Software Inc.’s(TIBX) fiscal fourth-quarter profit slipped 8.7% as the cloud computing platform provider’s rise in expenses masked a jump in revenue. However, shares slumped 12% to $21.60 premarket as the company provided current-quarter guidance that missed Wall Street estimates.
- [By Jake L’Ecuyer]
Equities Trading DOWN
Shares of TIBCO Software (NASDAQ: TIBX) were down 11.83 percent to $21.58 on Q4 results. Analysts at UBS downgraded the stock from Buy to Neutral.
- [By Dan Caplinger]
TIBCO Software (NASDAQ: TIBX ) will release its quarterly report on Thursday, and investors have looked increasingly uncertain about whether the enterprise infrastructure and IT integration software maker can continue to produce solid share-price gains. Even though the company has managed to fend off much larger rivals IBM (NYSE: IBM ) and Oracle (NYSE: ORCL ) thus far, TIBCO has a long way to go before it can ultimately declare victory over them and the rest of its competition.
Best Mid Cap Stocks To Invest In 2015: Takeda Pharmaceutical Co Ltd (TKPHF.PK)
Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. Advisors’ Opinion:
- [By Markus Aarnio]
Companies working on chemically synthesized siRNAs include Merck (MRK), through its subsidiary Sirna Therapeutics, Inc., Novartis (NVS), Takeda (TKPHF.PK), Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando, Quark, Silence Therapeutics plc, Tekmira (TKMR), Sylentis and Dicerna Pharmaceuticals, Inc.
- [By Alpha Exposure]
The most recent Affymax article states that Takeda withdrew from consideration for European approval "because they were doing the "root cause analysis" they would not be able to complete the investigation because it was still in process and "ongoing" despite the fact that severe reactions were not present at the time of the clinical trials." However, there is no evidence to support this conclusion. The truth is that we showed you an excerpt directly from the Committee for Medicinal Products for Human Use that stated the CHMP "was of the provisional opinion that Omontys could not have been approved" due to "study results indicating that Omontys may increase the risk of death or heart and circulatory problems." It is clear that the EU application was withdrawn because Takeda (TKPHF.PK) could not get Omontys approved due to its safety profile.
Best Mid Cap Stocks To Invest In 2015: Cytori Therapeutics Inc(CYTX)
Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical products and devices to enable the practice of regenerative medicine. Regenerative medicines focus on repairing or restoring lost or damaged tissue and cell function. Its principal products include the Celution family of products, which processes patients’ adipose-derived stem and regenerative cells (ADRCs) at the point of care. The Celution family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzyme reagents, and related instrumentation. Its core product, the Celution System, provides physicians with clinical grade stem and regenerative cells for use in the cosmetic and reconstructive surgery market. The company also provides PureGraft, a consumable product that provides grafts for use in aesthetic body contouring procedures. In addition, it sells the StemSource family of products worldwide, including in the United States, for research, as well as for the cryopreservation and storage of ADRCs. It offers the StemSource System as a standalone product, or as a part of a comprehensive suite of systems, equipment, and protocols collectively referred to as a StemSource Cell Bank. Further, the company develops Celution System, which has completed two clinical trials for applications in cardiovascular disease, wound healing, gastrointestinal disorders, stress urinary incontinence, liver and renal disease, spinal disc degeneration, and pelvic health conditions. It has strategic development and manufacturing joint venture agreement, and other related agreements with Olympus Corporation. The company was formerly known as MacroPore Biosurgery, Inc. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.
- [By James E. Brumley]
If you’re reading this, then odds are you already know that Cytori Therapeutics Inc. (NASDAQ:CYTX) is up a whopping 8% today. In some ways that’s encouraging, as it proves there’s a lot of trade-worthy momentum to be tapped. In other ways, however, it’s bad, because CYTX is overbought and ripe for a pullback. No matter how you’re seeing Cytori Therapeutics in the short run, though, when you take a step back and look at the longer-term picture, there’s a lot to like.
Best Mid Cap Stocks To Invest In 2015: Mattson Technology Inc.(MTSN)
Mattson Technology, Inc. engages in the design, manufacture, marketing, and support of semiconductor wafer processing equipment used in the fabrication of integrated circuits for the semiconductor industry worldwide. Its dry strip products include the SUPREMA strip system that incorporates its inductively coupled plasma (ICP) technology photoresist process module, and vacuum-based productivity platform for processing of sub 30 nm devices. The company?s rapid thermal processing products include the Helios and Helios XP systems for conventional annealing applications, and the Millios system for millisecond anneal applications. Its etch products comprise the paradigmE and Alpine that feature a proprietary Faraday-shielded ICP with etch bias control to provide process on-wafer performance. The company sells its products directly, as well as through distribution agreements to foundries, and memory and logic device manufacturers. Mattson Technology, Inc. was founded in 1988 and is headquartered in Fremont, California.
- [By Roberto Pedone]
Mattson Technology (MTSN) designs, manufactures and markets semiconductor wafer processing equipment used in the fabrication of integrated circuits. This stock closed up 5.1% to $2.25 in Tuesday’s trading session.
Tuesday’s Range: $2.15-$2.30
52-Week Range: $0.70-$2.55
Tuesday’s Volume: 593,000
Three-Month Average Volume: 825,998
From a technical perspective, MTSN bounced higher here back above its 50-day moving average at $2.23 with lighter-than-average volume. It looks like MTSN has now put in a double bottom chart pattern, since the stock has found some buying interest over the last month at $2.05 to $2.07. If that bottom can hold, then shares of MTSN will not set up to trigger a major breakout trade. That trade will hit if MTSN manages to take out some near-term overhead resistance levels at $2.40 to $2.52 and then once it clears its 52-week high at $2.55 with high volume.
Traders should now look for long-biased trades in MTSN as long as it’s trending above $2.07 to $2.05 and then once it sustains a move or close above those breakout levels with volume that hits near or above 825,998 shares. If that breakout hits soon, then MTSN will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are its next major overhead resistance levels at $3.17 to its three-year high at $3.30.
- [By Stephen Simpson, CFA]
Ultratech isn’t the only game in town, though, and there are multiple technologies and process steps that are going to play significant roles in the production of FinFETs and 3D circuits. With that, I would take a look at Mattson Technologies (MTSN), as this company has already accomplished the not-so-easy task of gaining meaningful share in the dry strip, rapid thermal processing (RTP), and etch markets despite competing with giants like Lam Research (LRCX), Applied Materials (AMAT), and Tokyo Electron (TOELY.PK).
Best Mid Cap Stocks To Invest In 2015: Fidelity National Financial Inc. (FNF)
Fidelity National Financial, Inc. provides title insurance, mortgage services, and diversified services in the United States. The company provides title insurance, escrow, and other title related services, including collection and trust activities, trustee’s sales guarantees, recordings, and reconveyances, as well as home warranty insurance to various customers in the residential and commercial market sectors of the real estate industry. It is also involved in the design, manufacture, remanufacture, market, and distribution of aftermarket and original equipment electrical components for automobiles, light trucks, heavy-duty trucks, and other vehicles worldwide. In addition, the company owns and operates restaurants comprising the O’Charley’s, Ninety Nine Restaurants, Max & Erma’s, Village Inn, Bakers Square, and Stoney River Legendary Steaks concepts in the United States. Fidelity National Financial, Inc. is headquartered in Jacksonville, Florida.
- [By Adam J. Wiederman]
Getty Images Bitcoin made headlines last year when the value of all outstanding pieces of the electronic currency reached nearly $10 billion. It’s not just speculators drawn to the new currency. Many businesses are also attempting to cash in on this growth: Several public companies, including Zynga (ZNGA) and Overstock.com (OSTK), accept Bitcoins as a form of payment. Venture capitalist Marc Andreessen’s firm has invested nearly $50 million in Bitcoin-related ventures, and it is looking to invest even more. And the Winklevoss twins — who notoriously accused Facebook’s (FB) Mark Zuckerberg of stealing their idea — have been “in dialogue” with the SEC about opening the first Bitcoin exchange-traded fund, according to Bloomberg. Yet a new survey from TheStreet.com (TST) reveals that 76 percent of consumers are not familiar with Bitcoin — and 79 percent would never consider owning a currency like it. Does this signal opportunity for savvy investors? Or is this a fad you’d be wise to avoid? The Basics of Bitcoin Bitcoin is a completely unregulated form of currency developed by an anonymous Japanese programmer (according to some apocryphal claims) as a completely digital, peer-to-peer payment system that is independent of national currencies (which, Bitcoin users argue, are all subject to the riskiness of the underlying country). Bitcoins are rewarded throughout the day to a “Bitcoin miner” whose computer solves a series of algorithms quicker than other miners. The puzzles become more difficult over time, so the calculations take longer and the computations require more computing power. There will eventually be a total of 21 million Bitcoins (12.4 million are in circulation today) and we won’t reach the point that they are effectively “mined out” until 2040. The value of a Bitcoin is supposed to be market-driven, meaning they’re worth whatever the two parties in a transaction value them as. For example, in one of the original Bitcoin transactions, a “mi
- [By Rich Duprey]
Title insurance company Fidelity National Financial (NYSE: FNF ) announced yesterday its third-quarter dividend of $0.16 per share, the same rate it’s paid for the past three quarters after raising the payout 14% from $0.14 per share.
Best Mid Cap Stocks To Invest In 2015: Gulfport Energy Corporation(GPOR)
Gulfport Energy Corporation engages in the exploration, development, and production of oil and natural gas properties. Its principal properties are located in the Louisiana Gulf Coast, in west Texas in the Permian Basin and in western Colorado in the Niobrara Formation. The company also holds acreage position in the Alberta oil sands in Canada; and interests in entities that operate in southeast Asia, including the Phu Horm gas field in Thailand, as well as leasehold interests in the Utica Shale in eastern Ohio. As of December 31, 2011, it had 19.4 million barrels of oil equivalent of proved reserves. The company is headquartered in Oklahoma City, Oklahoma.
- [By Ben Levisohn]
Shares of Penn Virginia have gained 8.5% to $14.01 at $3:08 p.m., putting it up 49% so far this year. Shares of EQT Corp. (EQT) have ticked up 0.2% to $100.23, while Devon Energy (DVN) has risen 0.5% to $64.54, EOG Resources (EOG) has advanced 0.6% to $179.84 and Gulfport Energy (GPOR) is up 0.1% at $64.87.
- [By Holly LaFon]
Another area that is intriguing to us is the North American energy sector which looks to have a number of interesting catalysts currently. While the energy sector is at present only a modest overweight in the portfolios, we have been encouraged by several trends taking place for a number of years. These positive developments are also having an impact that goes far beyond the energy sector itself. Many believe that the U.S. will become energy independent and possibly a net exporter of natural gas and oil (currently restricted by law) in the next decade. This opinion is based primarily on the development of new drilling techniques (i.e. horizontal drilling, and high pressure fracking) that have enabled companies to access oil and natural gas reserves in shale formations that were previously not economically viable. The ability to tap into this acreage is a game-changer in our view and is already having a tremendous impact on the economy. Employment rates in these mostly rura l areas surrounding the shale basins are very high and companies thus find hiring extremely competitive. Strong labor markets tend to create strong local economies. Oil States International (OIS) has been able to capitalize on this trend by providing housing and other services to oil service workers that are in demand in the area. CST Brands (CST) operates gas stations in Texas, but it is increasingly looking to broaden its product offering beyond fuel. Rail companies like Union Pacific (UNP), Canadian Pacific (CP), Kansas City Southern (KSU) and Genesee and Wyoming (GWR) have also benefited substantially. Given that shale areas are rural and often lacking infrastructure, substantial investment must be made to support drilling and production activities. Without pipelines in place, railroads have been the primary takeaway mechanism for moving production to the various clusters of refining capacity around the United States. In order to serve this demand, massive investment in railcars has been nee
- [By Jake L’Ecuyer]
PBF Energy (NYSE: PBF) tumbled 5.85 percent to $28.16 after the company priced secondary offering of 15 million shares at $28 per share. Gulfport Energy (NASDAQ: GPOR) was down, falling 6 percent to $55.66 after the company reported 2013 exit rate of 27,780 barrels of oil equivalent per day. RBC Capital downgraded Gulfport Energy from Outperform to Sector Perform and cut the price target from $64.00 to $61.00.
- [By Bret Jensen]
Gulfport Energy Corporation (GPOR) is an independent oil & gas company. The company’s principal properties are located along the Louisiana Gulf Coast; in the Utica Shale, eastern Ohio; in the Niobrara Formation, northwestern Colorado; and in the Bakken Formation, western North Dakota and eastern Montana.
Best Mid Cap Stocks To Invest In 2015: Dynegy Inc (DYN)
Dynegy Inc. (Dynegy), incorporated in 2007, is a holding company and conducts the business operations through its subsidiaries. Dynegy’s primary business is the production and sale of electric energy, capacity and ancillary services from the fleet of 16 operating power plants in six states totaling approximately 11,600 megawatts of generating capacity. The Company sells electric energy, capacity and ancillary services on a wholesale basis from its power generation facilities. Its customers include Regional Transmission Organization (RTOs) and Independent System Operators (ISOs), integrated utilities, municipalities, electric cooperatives, transmission and distribution utilities, industrial customers, power marketers, financial participants, such as banks and hedge funds, and other power generators. Dynegy operates in three segments: the Coal segment (Coal), the Gas Segment (Gas) and the Dynegy Northeast Segment (DNE). In September 2011, it acquired direct ownership of Dy negy Coal Holdco, LLC. In July 2012, the Company announced that it has filed a voluntary petition to reorganize under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York, Poughkeepsie Division. It emerged from bankruptcy, on October 1, 2012. In May 2013, the Company sold its Roseton power generation facility (Roseton) to a subsidiary of Castleton Commodities International LLC (CCI).
Dynegy’s Coal segment consists of four operating coal-fired power generation facilities and two operating natural gas-fired peaker facilities in Illinois with a total generating capacity of 3,132 megawatts. On November 17, 2011, it permanently retired the 176 megawatts Vermilion power generation facility. As of December 31, 2011, the facilities operated entirely within MISO. Its Coal segment is primarily a fleet of baseload coal facilities, located in Illinois. The MISO market includes all of Wisconsin and portions of Michigan, Kentucky, Indian! a, Illinois, Nebraska, Kansas, Missouri, Iowa, Minnesota, North Dakota, Montana and Manitoba, Canada. MISO is as an independent RTO.
Dynegy’s Gas segment consists of seven operating natural gas-fired power generation facilities located in California (two), Nevada (one), Illinois (one), Pennsylvania (one), New York (one), and Maine (one), and one fuel-oil fired power generation facility located in California, totaling 6,771 megawatts of electric generating capacity. On November 7, 2011, it deconsolidated DH, which indirectly owns all of its assets in the Gas segment. The PJM market includes all or parts of Delaware, Illinois, Indiana, Kentucky, Maryland, Michigan, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Virginia, West Virginia and the District of Columbia. The Company’s Kendall and Ontelaunee facilities located in Illinois and Pennsylvania operate in PJM with an aggregate net generating capacity of 1,780 megawatts.
Dynegy’s DNE segment consists of the Roseton and Danskammer facilities located in Newburgh, New York, with a total capacity of 1,693 megawatts. Its total of 1,570 megawatts of generation capacity relates to leased units at the two facilities. The Company’s Roseton and Danskammer facility sites are adjacent and share common resources, such as fuel handling, a docking terminal, personnel and certain associated systems.
- [By Bram de Haas]
Dynegy Inc (DYN) emerged from bankruptcy last year. The share price didn’t really go anywhere. In the meantime 2013 free cash flow guidance is being revised upward to $190 million – $215 million and a deal to take over capacity from Ameren Corp (AEE) is likely to be finalized in the 4th quarter. On the basis of current cash flow, the company is fairly valued. If the Ameren facilities are added in, the cash flow of the combined facilities is greatly undervalued.
- [By Justin Loiseau]
With a successful $900 million asset sale to Dynegy (NYSE: DYN ) in March, Ameren has three leftover gas-fired energy centers it still needs to offload.
- [By Justin Loiseau]
Ameren (NYSE: AEE ) and Dynegy (NYSE: DYN ) aren’t letting regulatory snafus get in the way of their plans. The two companies published a statement this week assuring investors that despite the Illinois Pollution Control Board’s denial of a variance relief transfer, Dynegy still plans to acquire Ameren Energy Resources.
Best Mid Cap Stocks To Invest In 2015: UTStarcom Inc.(UTSI)
UTStarcom Holdings Corp. designs and sells Internet protocol (IP)-based telecommunications infrastructure products to telecommunications service providers and operators worldwide. It provides solutions in IPTV, interactive (iD) TV, Internet TV, and broadband, as well as related installation and maintenance services. It offers multimedia communications products, including RollingStream, an IPTV solution that enables a service provider to deliver broadcast television and on-demand video services to residential and commercial premises over a switched network architecture; mSwitch, a next generation network solution that enables service providers to migrate from existing circuit platforms to a next generation IP-based switch architecture, or to launch new applications in new deployment environments that have no legacy infrastructure; and a personal access system, as well as provides related consulting, technical, project, quality, and maintenance support-level services. The co mpany also provides broadband infrastructure products comprising broadband access products consisting of multi-service access node products; digital subscriber line (DSL) products, such as DSL modems, set-top boxes, and voice over the internet devices for residential and business customers; and gigabit Ethernet passive optical network products, as well as optical transport products, including packet optical transport network products, multi-service transport platform, and resilient packet ring. It sells its products through direct sales, original equipment manufacturers, distributors, resellers, agents, and licensees primarily in China, Japan, India, and other Asian markets; the United States; Latin America; and Europe. The company was formerly known as UTStarcom, Inc. and changed its name to UTStarcom Holdings Corp. in June 2011. UTStarcom Holdings Corp. was founded in 1991 and is headquartered in Beijing, China.
- [By Dan Radovsky]
Today the satellite pay-TV provider filed a letter with the Federal Communications Commission pointing to media reports about a Department of Justice investigation into charges of bribery by telecommunications equipment provider UTStarcom (NASDAQ: UTSI ) , also known as UTSI. The DOJ says the company gave $7 million to Chinese government officials in return for telecommunications sales contracts. In 2009 UTStarcom admitted to bribery and agreed to pay $1.5 million.
- [By Dan Radovsky]
As expected, DISH was ready with a response, but it wasn’t one that defended its numbers. Instead, DISH filed a letter with the Federal Communications Commission repeating media accounts regarding a Department of Justice investigation of bribery charges against telecommunications equipment provider UTStarcom (NASDAQ: UTSI ) . The DISH filing says Masayoshi Son was chairman of the board of UTStarcom during part of the time in which the bribery was said to occur.
Best Mid Cap Stocks To Invest In 2015: Clovis Oncology Inc (CLVS)
Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.
CO-101 – a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine
CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.
CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor
CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.
The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line trea tment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.
CO-338-a PARP Inhibitor
CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!
The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.
- [By Jake L’Ecuyer]
Clovis Oncology (NASDAQ: CLVS) was also up, gaining 7.26 percent to $79.35 after the company announced 2014 objectives and financial outlook. The company projected to initiate three global registration studies for CO-1686.
- [By John Udovich]
On Wednesday, small cap cancer stock Clovis Oncology Inc (NASDAQ: CLVS) soared 16.68% after announcing a $200 million cancer deal plus the biotech has more than tripled since late 2011, meaning it might be time to take a closer look at what’s driving the stock higher as well as look at the performance of biotech ETF benchmarks like iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
- [By John Udovich]
Bubble talk, biotech IPO setbacks plus news about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:
Why There is No Biotech Bubble & Where to Look for Value in Biotech. Marshall Gordon, the Director and senior health-care analyst of ClearBridge Investments, was recently interviewed by Barron’s where he stated his belief that there is no biotech bubble because biotech stocks have delivered new drugs and have shown an ability to innovate. With that said, he added that the sector got ahead of itself while some biotechs suffered setbacks plus hedge funds decided to trim risk from their portfolios. Nevertheless, Marshall likes or is watching mid cap biotechs BioMarin Pharmaceutical Inc (NASDAQ: BMRN) and Pharmacyclics, Inc (NASDAQ: PCYC) along with small cap biotechs Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Clovis Oncology Inc (NASDAQ: CLVS). He also added that recent biotech IPOs have been lesser quality names than earlier offerings. A Trio of Biotech IPO Setbacks. FierceBiotech has summarized how a trio of biotech IPO have suffered setbacks. Specifically, Relypsa (NASDAQ: RLYP), a late-stage biotech developing a treatment for hyperkalemia, slashed its asking price on 6.9 million shares to $12 a share to raise $82 million from a range of $16 to $19 a share while Xencor (NASDAQ: XNCR), a biotech developing antibodies for severe autoimmune/allergic diseases and cancer, has dropped its IPO price to $7 a share to raise $75 million from a range of $14 to $16. Meanwhile, Celladon, which is developing a first-in-class gene therapy for patients with systolic heart failure, has postponed its IPO citing poor market conditions. Coming Biotech IPOs. Nevertheless, FierceBiotech has noted that GeNO Healthcare (NASDAQ: GNO) is looking to raise $50 million for its new, patient-friendly approach for delivering inhaled nitric oxide on the
- [By Sean Williams]
What: Shares of Clovis Oncology (NASDAQ: CLVS ) , a biopharmaceutical company that’s developing anti-cancer therapies, vaulted higher by as much as 136% (that’s not a typo!) after reporting positive data on two early stage experimental treatments — CO-1686 in EGFR-mutant non-small cell lung cancer (NSCLC) and Rucaparib in a monotherapy study of solid tumors — at the American Society of Clinical Oncology’s annual meeting.